News Focus
News Focus
icon url

vator

06/20/23 2:59 AM

#602930 RE: ATLnsider #602910

Thanks. Past day a great deal of good information. Especially on tissue agnostic. Keytruda had to do POST APPROVAL studies. A great deal better than full blown trials. That is what I expected.

Once you are making money, collecting data on people using it at some centers gets much easier.